These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 27143349)

  • 1. Adding glucose-lowering agents delays insulin initiation and prolongs hyperglycemia.
    Hugie C; Waterbury NV; Alexander B; Shaw RF; Egge JA
    Am J Manag Care; 2016 Apr; 22(4):e134-40. PubMed ID: 27143349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initiation of insulin among veterans with type 2 diabetes and sustained elevation of A1c.
    Parchman ML; Wang CP
    Prim Care Diabetes; 2012 Apr; 6(1):19-25. PubMed ID: 21840276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).
    Bolli GB; Riddle MC; Bergenstal RM; Ziemen M; Sestakauskas K; Goyeau H; Home PD;
    Diabetes Obes Metab; 2015 Apr; 17(4):386-94. PubMed ID: 25641260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment patterns among older patients with type 2 diabetes in the United States: a retrospective cohort study.
    Fu H; Curtis BH; Schuster DP; Festa A; Kendall DM
    Diabetes Technol Ther; 2014 Dec; 16(12):833-9. PubMed ID: 25068375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin-Treated Diabetes.
    Karter AJ; Parker MM; Moffet HH; Gilliam LK; Dlott R
    JAMA; 2021 Jun; 325(22):2273-2284. PubMed ID: 34077502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
    Grabner M; Peng X; Geremakis C; Bae J
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tight glycemic control and use of hypoglycemic medications in older veterans with type 2 diabetes and comorbid dementia.
    Thorpe CT; Gellad WF; Good CB; Zhang S; Zhao X; Mor M; Fine MJ
    Diabetes Care; 2015 Apr; 38(4):588-95. PubMed ID: 25592195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Slow Titration and Delayed Intensification of Basal Insulin Among Patients with Type 2 Diabetes.
    Mocarski M; Yeaw J; Divino V; DeKoven M; Guerrero G; Langer J; Thorsted BL
    J Manag Care Spec Pharm; 2018 Apr; 24(4):390-400. PubMed ID: 29406841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures.
    Lingvay I; Chao J; Dalal MR; Meneghini LF
    Diabetes Technol Ther; 2017 May; 19(5):315-322. PubMed ID: 28467113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and Economic Outcomes Associated With the Timing of Initiation of Basal Insulin in Patients With Type 2 Diabetes Mellitus Previously Treated With Oral Antidiabetes Drugs.
    Levin P; Zhou S; Durden E; Farr AM; Gill J; Wei W
    Clin Ther; 2016 Jan; 38(1):110-21. PubMed ID: 26681210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.
    Diamant M; Nauck MA; Shaginian R; Malone JK; Cleall S; Reaney M; de Vries D; Hoogwerf BJ; MacConell L; Wolffenbuttel BH;
    Diabetes Care; 2014 Oct; 37(10):2763-73. PubMed ID: 25011946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis.
    Buysman EK; Chow W; Henk HJ; Rupnow MF
    BMC Endocr Disord; 2015 Nov; 15():67. PubMed ID: 26527413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liberating A1C goals in older adults may not protect against the risk of hypoglycemia.
    Munshi MN; Slyne C; Segal AR; Saul N; Lyons C; Weinger K
    J Diabetes Complications; 2017 Jul; 31(7):1197-1199. PubMed ID: 28343792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycemic and weight changes after persistent use of incident oral diabetes therapy: a Veterans Administration retrospective cohort study.
    Huizinga MM; Roumie CL; Greevy RA; Liu X; Murff HJ; Hung AM; Grijalva CG; Griffin MR
    Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1108-12. PubMed ID: 20878643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage Population.
    Visaria J; Uzoigwe C; Swift C; Dang-Tan T; Paprocki Y; Willey VJ
    Clin Ther; 2021 May; 43(5):808-821. PubMed ID: 33785221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study.
    Gupta S; Wang H; Skolnik N; Tong L; Liebert RM; Lee LK; Stella P; Cali A; Preblick R
    Adv Ther; 2018 Jan; 35(1):43-55. PubMed ID: 29313285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Collaborative drug therapy management for initiating and adjusting insulin therapy in patients with type 2 diabetes mellitus.
    Rochester CD; Leon N; Dombrowski R; Haines ST
    Am J Health Syst Pharm; 2010 Jan; 67(1):42-8. PubMed ID: 20044368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Proton Pump Inhibitors on Glycemic Control in Patients with Type 2 Diabetes.
    Villegas K; Meier JL; Long M; Lopez J; Swislocki A
    Metab Syndr Relat Disord; 2019 May; 17(4):192-196. PubMed ID: 30730235
    [No Abstract]   [Full Text] [Related]  

  • 19. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1).
    Riddle MC; Bolli GB; Ziemen M; Muehlen-Bartmer I; Bizet F; Home PD;
    Diabetes Care; 2014 Oct; 37(10):2755-62. PubMed ID: 25078900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the metformin initiation rate in veterans with newly identified type 2 diabetes.
    Zenti KJ; Meyer MM; Waterbury NV; Egge JA
    Prim Care Diabetes; 2021 Jun; 15(3):578-581. PubMed ID: 33602605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.